The SmartPak™ Pharmacy Equine Product Information Sheet

Equioxx® Oral Paste

Common Drug Name – Firocoxib

How Supplied by SmartPak –Each syringe contains 6.93 grams of Equioxx paste (0.82% Firocoxib), sufficient to treat a 1250lb horse.

Category – Equioxx belongs to the coxib class of non-narcotic, non-steroidal anti-inflammatory drugs (NSAIDs).

Caution - Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Indications (Uses) –Equioxx is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses.

Dosage and Administration – The recommended dosage of Equioxx for oral administration in horses is 0.045mg/lb (0.1 mg/kg) of body weight once daily for up to 14 days. Each marking on the syringe will treat 250lbs of body weight, and each notch corresponds to approximately a 50lb weight increment. To deliver the correct dose, round the horse's body weight up to the nearest 50lb increment (if the body weight is an exact 50lb increment, do not round up). Unlock the knurled ring on the syringe plunger by rotating it ¼ turn. Slide the knurled ring along the plunger shaft so that the side nearest the barrel is at the appropriate 50lb weight notch. Rotate the plunger ring ¼ turn to lock it in place and ensure it is locked. Equioxx may be given with or without food.

Contraindications – Horses with hypersensitivity to Firocoxib or other NSAIDs should not receive Equioxx.

Human Warnings – Not for human use. Keep out of reach of children. Consult a physician in case of accidental ingestion by humans.

Warnings – For oral use in horses only. Do not use in horses intended for human consumption.

Precautions – Horses should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests should be conducted to establish hematological and serum biochemical baseline data before and periodically during administration of any NSAID. Owners should observe for signs of potential drug toxicity. Treatment with Equioxx should be terminated if signs such as inappetance, colic, abnormal feces, or lethargy are observed. As a class, cyclooxygenase inhibitory NSAIDs may be associated with renal and GI toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Patients at greatest risk for adverse events are those that are dehydrated, on diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached or avoided. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Since many NSAIDs possess the potential to produce GI ulcerations, concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided or closely monitored. The concomitant use of protein bound drugs with Equioxx has not been

studied in horses. The safe use of Equioxx in horses less than one year in age, horses used for breeding, or in pregnant or lactating mares has not been evaluated. Consider appropriate washout times when switching from one NSAID to another NSAID or corticosteroid.

Adverse reactions (side effects) – Adverse reactions may include erosions and ulcers of the gums, tongue, lips and face, weight loss, colic, diarrhea, or icterus. Serious adverse reactions associated with this drug class can occur without warning and, in rare situations, results in death. Owners should discontinue NSAID therapy and contact their veterinarian immediately if any of these signs of intolerance are observed.

Storage Conditions: Store below 86F. Brief excursions up to 104F are permitted.

Marketed by:
Merial Limited
Duluth, GA 30096-4640

Rev. 1/08

SmartPak™
40 Grissom Road, Suite 500
Plymouth, MA 02360
Phone: 1-800-431-4194
Fax: 1-800-431-4179
www.SmartPak.com